Business
MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders
NEW YORK--(BUSINESS WIRE)-- MedTech Acquisition Corporation (Nasdaq: MTAC) (“MedTech” or the “Company”) today announced that it convened and then adjourned,
About this update from Trisalus Life Sciences, Inc.
[{"type":"text","content":" NEW YORK--(BUSINESS WIRE)--\nMedTech Acquisition Corporation (Nasdaq: MTAC) (“MedTech” or the “Company”) today announced that it convened and then adjourned, without conducting any business, its special meeting of stockholders (the “Special Meeting”). The Special Meeting is being held to vote on certain proposals related to the proposed business combination (the “Business Combination”) with TriSalus Life Sciences (“TriSalus”).\n\n\nThe Special Meeting has been adjourned until 11:00 a.m. Eastern Time on August 8, 2023. The Special Meeting will still be held virtually via webcast, and stockholders may attend and participate online by visiting https://www.cstproxy.com/medtechacquisition/sm2023. Participants will be able to listen to the meeting live, submit questions and vote.\n\n\nPrior to the Special Meeting, on the morning of August 2, 2023, MTAC filed a Current Report on Form 8-K regarding the written response received by TriSalus from the FDA in reference to a Type B meeting request for TriSalus’ PERIO-01 clinical program. Stockholders may obtain a free copy of the Form 8-K, and other documents containing important information about the Company and TriSalus, through the website maintained by the SEC at www.sec.gov.\n\n\nIn connection with the adjournment of the Special Meeting, the Company has extended the deadline for public stockholders to submit their shares for redemption to 5:00 p.m. Eastern Time on August 4, 2023. Stockholders who wish to withdraw their previously submitted redemption requests may do so prior to the vote at the Special Meeting by requesting that the Company's transfer agent, Continental Stock Transfer & Trust Company, return such shares.\n\n\nAbout MedTech Acquisition Corporation\n\n\nMedTech Acquisition Corporation (Nasdaq: MTAC) is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. MedTech has stated a focus on the medical technology industry in the United States and other developed countries.\n\n\nParticipation in Solicitation\n\n\nThe Company and TriSalus and their respective directors and executive officers, under SEC rules, may be deemed to be participants in the solicitation of proxies of the Company’s stockholders in connection with the Busin...